Navigation Links
New discovery brings hope to treatment of lymphatic diseases
Date:8/10/2009

LEXINGTON, Ky. (Aug. 10, 2009) − Researchers in the laboratory of Dr. Jayakrishna Ambati at the University of Kentucky have discovered the first naturally occurring molecule that selectively blocks lymphatic vessel growth. In an article in the Aug. 9, 2009 online edition of Nature Medicine, they report the identification of a new molecule known as soluble VEGFR-2 that blocks lymphangiogenesis the growth of lymphatics but not blood vessel growth.

The twin circulatory systems of mammals - blood and lymphatic - are intricately intertwined, both anatomically and functionally. Until now it has been difficult to selectively target one without affecting the other. The lymphatic vessel network is essential for transporting fluids, molecules, and immune cells. It is crucial for wound healing and immune defense. Disturbances in the lymphatics are involved in diseases as varied as lymphedema, transplant rejection, and tumor metastasis, which collectively affect hundreds of millions of people worldwide.

This article, whose lead author is Dr. Romulo Albuquerque, currently a medical student in the UK College of Medicine, showed that soluble VEGFR-2 specifically blocks lymphatic vessel growth both during development and following injury by blocking VEGF-C, a powerful lymphatic growth factor. It also reports that loss of soluble VEGFR-2 during development led to the spontaneous invasion of lymphatic vessels, but not blood vessels, into the cornea, solving the long-standing mystery of why the cornea is normally devoid of lymphatics. Soluble VEGFR-2 was also required for normal development of lymphatics in the skin.

Importantly, administration of soluble VEGFR-2 to mice following corneal transplantation nearly eliminated graft rejection. This finding might also be applicable in kidney transplant rejection because it is known that lymphatic vessels are the culprit in the rejection of that organ as well. In addition, it challenges the prevailing dogma that abnormal blood vessels are responsible for transplant rejection.

The Ambati group also studied a childhood tumor known as lymphangioma, which is estimated to affect 1 in 50 babies and for which there is no satisfactory medical treatment. Administration of soluble VEGFR-2 blocked the growth of lymphangioma cells isolated from children with this tumor. Because this molecule spares blood vessels, it might offer a safer and more targeted treatment for this pediatric tumor. The potential benefit of modulating soluble VEGFR-2 in other diseases such lymphedema due to filariasis and or following surgery for breast cancer, as well as in tumor metastasis, are also under study.

"This paper by Dr. Ambati and his coworkers represents another in a line of highly novel and important findings from their laboratory," said Patricia A. D'Amore, Professor of Ophthalmology and Pathology, Harvard Medical School and Senior Scientist at the Schepens Eye Research Institute.

"The report of the first endogenous inhibitor of lymphangiogenesis is an exciting development and holds great therapeutic promise for a number of pathologies in which lymphatic growth is a serious complication."


'/>"/>

Contact: Ann Blackford
ann.blackford@uky.edu
859-312-3587
University of Kentucky
Source:Eurekalert

Related medicine news :

1. Immune System Gene Discovery Sheds Light on Staph Infections
2. Cell Discovery May Bring Science Closer to Diabetes Cure
3. The Psychology of Frailty: An Identity Crisis Among the Elderly - Alzheimers Drug Discovery Foundations Dr. Howard Fillit to Co-Chair Symposium
4. Toronto researchers discovery points to a new treatment avenue for acute myeloid leukemia
5. Scientists Gather to Discuss Novel Uses of Caliper Life Sciences Discovery Platforms and Technology
6. Discovery Points to Regulation of Calcium Metabolism
7. IDRI Awarded $314,500 Grant From Murdock Trust to Expand TB Drug Discovery Program
8. Asthma Discovery May Lead to Better Treatments
9. Microsoft to Showcase Clinical Trial Solutions From Discovery to Approvals at Drug Information Associations 2009 Annual Meeting
10. Gaiam and Discovery Communications Announce Exclusive Licensing Deal
11. Mayo Genomic Discovery: Protecting Kidney Function During Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 29, 2017 , ... ... pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March ... common questions regarding thyroid function. , Dr. Izabella Wentz is a licensed ...
(Date:3/28/2017)... NY (PRWEB) , ... March 28, 2017 , ... ... process management software and services, is proud to announce it has joined the ... professional association representing the interests of chronically ill, disabled, and dying Americans of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a leader in the ... Systems), the iSAFE and the iSAFE Plus. These iSAFE products are the most affordable ... the iSAFE and iSAFE Plus offer direct GPS Location and two-way calling with the ...
(Date:3/28/2017)... ... 28, 2017 , ... Usually, the impending arrival of warmer weather means the ... about a double chin, this means more anxiety than elation. The cosmetic dermatology experts ... people, a double chin is undesirable,” Dr. Goldman said, “but it seems doubly so ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ - StarFish ... medical device development firm, announced today that it has ... -based medical device industrial design and productization organization.  ... throughout North America with easier ... talent spanning the design, engineering, regulatory, and manufacturing process. ...
(Date:3/28/2017)... March 28, 2017  Akcea Therapeutics, a subsidiary of Ionis ... company,s board of directors: ... Gabrieli will serve as chairman of the board of Akcea ... commercial officer of Forest Laboratories. Sandford ... "We are excited to announce this ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology: